Visit Our Blog
  • FDNA TELEHEALTH
  • Products
    • Face2Gene Labs
    • Face2Gene Clinic
  • About FDNA
  • News & Press
    • In The News
    • Press Releases
  • Contact
  • FDNA Insights

FDNA Insights

Categories
  • All
  • 2018
  • ACMG
  • Case Study
  • Events/Conferences
  • Face2Gene
  • Genomics
  • Pharma
  • Pharma
  • Phenotyping
  • Rare Diseases
  • Scientific Abstracts
  • Talks
  • Technology
  • Uncategorized
  • Videos
  • Webinar

FDNA and Face2Gene Featured at ESHG

June 25, 2018

By Christen Baglaneas

Events/Conferences,Face2Gene,Genomics,Scientific Abstracts,Talks

 

A flock of researchers from around the globe shared their findings in dysmorphology and molecular genetics at this year’s ESHG as a part of FDNA’s corporate satellite talk and various scientific posters.

Karin Weiss (Rambam Health Care Campus, Haifa, Israel) presented her further work on Sifrim Hitz Weiss Syndrome (SIHIWES), a recently described form of syndromic intellectual disability identified through reverse phenotyping.

“When you come to classify the new case, there are some difficulties because the phenotype is not specific enough to make the diagnosis,” she said, adding “in this condition all the variants are missense.”

Weiss attempted to train Face2Gene on known SIHIWES cases and successfully taught the system to separate healthy individuals from those with SIHIWES, although the rate at which the system separates SIHIWES from different syndromes was not statistically significant. However, the system was able to notice the possibility of SIHIWES in two patients whose exome sequencing indicated de novo mutations outside the “hotspot” on the CHD4 gene, leading her to conclude that, “facial recognition can aid in variant interpretation probably by supporting a specific variant, not excluding.”

Antonio Martinez-Monseny, MD, (Hospital Sant Joan de Deu, Barcelona, Spain) reviewed how his team used Face2Gene to test several hypotheses, first training the system on PMM2-CDG with a mean accuracy of about 75 percent when comparing confirmed cases to unaffected controls and diagnosed cases of Angelman syndrome. He confirmed that there is indeed a “face” for the syndrome and that it is recognizable across ages, making it easier for clinicians to diagnose the syndrome at an earlier age and, he said, potentially improving access to therapies.

Peter Krawitz, MD, PhD (University of Bonn, Germany), explained how a web-based filtering and annotation tool, Deep Phenotyping, Deep Learning (DPDL) is powering his Prioritization of Exome Data by Image Analysis (PEDIA) approach with help from Face2Gene.

“DPDL can integrate multiple scores from the molecular and phenotypic level,” he noted. Currently, clinicians can use DPDL via the website, but it will soon be available through Face2Gene LABS as well.

Krawitz, who is also FDNA’s Chief Data Science Officer, emphasized how combining phenotypic and molecular information refines the results either could give alone.

“In a routine setting this will speed up your analysis from maybe several days to several hours,” he said.

Jean Tori Pantel (Charité – Universitätsmedizin Berlin, Germany) demonstrated the RESEARCH application with Face2Gene, which she is using as part of her thesis investigating computer vision applications for recognizing inborn errors of metabolism. Her lab was able to create separate masks (composite facial photos) for types of mucopolysaccharidoses that were previously undifferentiated. In the process, she created cohorts of varying size with and without confounding factors, eventually concluding that the distinguishability of cohorts improves as the cohort sizes increase, although the achievable maximum is still unclear.

Tzung Hsieh (Institute for Genomic Statistics and Bioinformatics, Bonn, Germany), whose poster was nominated for a “Best Poster” award, researched how patients with mutations in similar molecular pathways compare phenotypically.

Idan Menashe, PhD (Ben Gurion University of the Negev, Beersheva, Israel), shared his research on facial dysmorphisms as biomarkers for autism spectrum disorder. Using a cohort of 81 patients at the Negev Autism Center, Menashe and his team used the Face2Gene deep convolutional neural network to evaluate the photos, as well as those of controls, and compare the average faces of the case group and the control group. The groups showed clear separation, with a p-value less than 0.001. His team also evaluated the specific areas responsible for the separation and concluded that the upper facial area (eyes and nose) are most informative to the system.

In addition to these presentations,  Yaron Gurovich,  Karen Gripp, MD,  and Ben Pode-Shakked, MD had scientific posters at ESHG showcasing how Face2Gene can be applied to research and how FDNA is improving the suite of phenotyping applications.

More entries about Events/Conferences

Rare Diseases
 

A Rare Disease Day Reflection

Rare diseases affect roughly 30 million Americans, yet only 5 percent of the estimated 7,000 known rare diseases have cures Read more

Events/Conferences
 

What to Do and See at ASHG 2018

San Diego, CA – The FDNA team is excited to be back at the American Society of Human Genetics (ASHG) Read more

Events/Conferences
 

AI in Healthcare: Separating the Hype from the Hope

FDNA’s CEO Dekel Gelbman recently spoke to hundreds of leaders during the Stanford Big Data in Precision Health Summit. The Read more

Events/Conferences
 

FDNA and Face2Gene Featured at ESHG

  A flock of researchers from around the globe shared their findings in dysmorphology and molecular genetics at this year’s Read more

Events/Conferences
 

What to Do and See at ESHG

The European Society of Human Genetics (ESHG) 42nd Annual  Meeting 2018 MiCo – Milano Congressi · Milan, Italy · June Read more

Events/Conferences
 

The Road to Precision Medicine: Balancing Ethics and Efficiency

Artificial intelligence has increasingly become the basis for advancing precision medicine. Tomorrow, at the ReWork Deep Learning in Healthcare Summit Read more

Pharma
 

FDNA’s Keynote at ePharma: Using Next-Generation Phenotyping For Precision Medicine Across the Pharma Value Chain

NOTE: This post is based on a presentation made at the March 2018 ePharma conference in New York City.   Read more

Events/Conferences
 

What to Do and See at ACMG

The American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting 2018 Charlotte Convention Center · Charlotte, North Carolina · April 10-14, 2018 Read more

Events/Conferences
 

Greenwood Genetic’s Journey: Partnering to Improve Precision Medicine

In its 44 year history, Greenwood Genetic Center (GGC) has seen over 80,000 patient cases. That’s a lot of data. Read more

Events/Conferences
 

Happening at HIMMS: Precision Medicine Through Next-Generation Phenotyping—A Customer’s Journey

HIMSS Conference, Microsoft booth Thursday, March 7 3:40 PM PST Las Vegas, Nevada   As over 40,000 health IT professionals, Read more

Events/Conferences
 

FDNA Announces Genomics Collaborative® at a Global Innovation Summit

English | Spanish In a packed auditorium at Mexico City’s CENTRO University, FDNA’s Senior Director of Marketing, Jeff Daniels, announced Read more

Events/Conferences
 

Drug Delivery Partnership: Precision Medicine Drives Discovery, Development and Commercialization in Pharma

In an era of breakthrough advancements in healthcare, it is hard to believe that 90% of blockbuster medicines are only Read more

Events/Conferences
 

What to Do and See at ASHG

The American Society of Human Genetics 67th Annual Meeting (ASHG 2017) Orange County Convention Center · Orlando, Florida October 17-21, Read more

Events/Conferences
 

FDNA Presents Rare Disease Technologies at the 2017 Precision Medicine Summit at Boston Children’s Hospital

The Division of Genetics and Genomics Department of Medicine at Boston Children’s Hospital will present their exciting new Fall Precision Read more

Events/Conferences
 

Disorder: The Rare Disease Film Festival

Disorder: The Rare Disease Film Festival will be held October 2 & 3, 2017 in Boston, MA. This is a new event Read more

Events/Conferences
 

What to Do and See at ESHG 2017 in Copenhagen

Annual Clinical Genetics Meeting (ESHG 2017) Bella Center Copenhagen, Copenhagen, Denmark May 27-30, 2017 Copenhagen, Denmark – The time is yet again Read more

Rare Diseases
 

New Facial Analysis Discoveries for RASopathy Syndromes in the Year of Discovery

  In March, FDNA reached out to clinicians and patients globally as part of the Year of Discovery to collect Read more

Rare Diseases
 

FDNA Partners with Blueprint Genetics to Spotlight RASopathies During the Year of Discovery

FDNA’s Year of Discovery Initiative will spotlight a different genetic syndrome group each month as part of their mission to Read more

Events/Conferences
 

What to Do and See at ACMG 2017 in Phoenix, AZ

Annual Clinical Genetics Meeting (ACMG 2017) Phoenix Convention Center, Phoenix, Arizona March 21-25, 2017 Phoenix, Arizona – With ACMG just over Read more

Rare Diseases
 

FDNA Launches “Year of Discovery” for Rare Disease Day

FDNA Launches “Year of Discovery” for Rare Disease Day Boston-based health and tech start-up calls on patients and clinicians to share Read more

  • Contact Us
  • Privacy Policy
  • Terms of Use

Signup for News


* These fields are required.

© 2011-2021 FDNA INC. www.FDNA.com. All rights reserved.

Face2Gene is a search and reference tool provided for informational purposes and not intended to replace the clinician’s judgment or experience, nor should it be used to diagnose or treat medical conditions.